Testing immunotherapy with chemo after lung cancer surgery
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding an immunotherapy medicine to standard chemotherapy after surgery can improve outcomes for some people with non-small cell lung cancer. It may help by boosting the immune system to reduce the chance the cancer comes back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re at least 18 years old, and you can do study visits well (ECOG 0–1).
- Your lung cancer was fully removed by surgery with no cancer left at the edges (R0 resection).
- You have the right tumor test results: no EGFR exon 19 deletion or EGFR L858R, and no ALK rearrangement (this applies to non-squamous lung cancer).
- Your tumor has been tested for PD-L1 using an approved lab test method.
- You haven’t had chemo or immunotherapy (neoadjuvant or adjuvant) for this lung cancer before.
- You meet key safety checks (no serious uncontrolled illness, no past non-infectious steroid-requiring lung inflammation, and blood/organ tests in range).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving immunotherapy (durvalumab) after surgery can help prevent lung cancer from coming back if you already had a complete response to chemo and immunotherapy before surgery. It is for people with early-stage non-small cell lung cancer who had no cancer left after treatment.
This trial compares giving immunotherapy before and after surgery versus only after surgery for people with early-stage but advanced lung cancer. It aims to see which timing might better help keep the cancer from coming back.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
This study tests whether doing surgery only after checking if the tumor shrinks with chemo-immunotherapy is safe and effective for people with locally advanced lung cancer. It may help avoid surgery if the cancer hasn't responded well.
This trial tests whether giving a type of immunotherapy (sintilimab) along with chemotherapy before and after surgery to remove the main lung tumor can help people with advanced non-small cell lung cancer. The goal is to see if this approach improves outcomes compared to standard treatment.
This trial tests a combination of chemotherapy and immunotherapy given before surgery for stage II or III non-small cell lung cancer. Doctors will look at biomarkers in your blood and tissue to see how the cancer responds, which could help guide future treatments.
Hear when a new Lung Non-Squamous Non-Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.